203519-37-3

Usage

Uses

Used in Pharmaceutical Industry:
ERT-BUTYL 4-(6-CHLORO-2-METHYL-4-PYRIMIDINYL)TETRAHYDRO-1(2H)-PYRAZINECARBOXYLATE is used as a pharmaceutical compound for its biological activity, specifically in the inhibition of certain enzymes. This makes it a promising candidate for the development of new drugs targeting various diseases and conditions.

InChI:InChI=1/C14H21ClN4O2/c1-10-16-11(15)9-12(17-10)18-5-7-19(8-6-18)13(20)21-14(2,3)4/h9H,5-8H2,1-4H3

Upstream product

• 1780-26-3 2,4-dichloro-2-methylpyrimidine 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 3934-20-1 2,6-Dichloropyrimidine 

Downstream Products

• 1258391-83-1 3-(2-(2-methyl-6-(piperazin-1-yl)pyrimidin-4-ylamino)thiazolo[5,4-b]pyridin-5-yl)-N-(3-(trifluoromethyl)phenyl)benzamide 
• 936845-85-1 4-[6-(5-formyl-thiazol-2-ylamino)-2-methyl-pyrimidin-4-yl]-piperazine-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

Compounds as syk kinase inhibitors

The present invention relates to a compound of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by inhibition of Syk kinase.

PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF SPHINGOSINE KINASE

The present invention relates to compounds that are useful as inhibitors of the activity of one or more isoforms of sphingosine kinase. Particularly, although not exclusively, the present invention also relates to pharmaceutical compositions comprising th

THIAZOLE INHIBITORS TARGETING RESISTANT AND KINASE MUTATIONS

A compound is provided, having the general structure (A): wherein A is an aryl or heteroaryl group, Y is a hydrophobic linking moiety, and L is a substitutent. The compound (A) can be used for treatment of various angiogenic-associated or hematologic disorders, such as myeloproliferative disorders in patients who do not respond to kinase-inhibition therapy that comprises administering currently used medications.

Substituted pyrimidine derivatives and their pharmaceutical use

PCT No. PCT/GB97/02029 Sec. 371 Date Feb. 12, 1999 Sec. 102(e) Date Feb. 12, 1999 PCT Filed Jul. 25, 1997 PCT Pub. No. WO98/06705 PCT Pub. Date Feb. 19, 1998This invention concerns heterocyclic derivatives which are useful in inhibiting oxido-squalene cyclase, processes for their preparation and pharmaceutical compositions containing them. The present invention is also concerned with heterocyclic derivatives capable of inhibiting cholesterol biosynthesis and hence in lowering cholesterol levels in blood plasma. The present invention also relates to methods of using such heterocyclic derivatives in diseases and medical conditions such as hypercholesterolemia and atherosclerosis.